Paijin Biotechnology

Chongqing Paijin Biotechnology Co., Ltd. was established in 2013. It is a high-tech enterprise specializing in the R&D, production and sales of gene protein recombination and peptide drugs. The company is located in Shuitu High-tech Industrialization Park, Liangjiang New Area, Chongqing, and possesses R&D technology platforms and an office R&D building, three workshops put into use (1500L CDMO, 3000L enzyme production, 2000L biological intermediates), and comprehensive quality testing laboratories. The company's wholly-owned subsidiary Chongqing Aimeidi Biotechnology Co., Ltd. specializes in the production and global sales of recombinant industrial proteases, and ZYME BIOTECH INC. is engaged in innovative R&D of biopharmaceuticals. The company's core team comes from doctors who returned from the United States and has advanced R&D models and rich experience in the field of biopharmaceutical R&D.
Up to now, multiple self-developed biopharmaceuticals of the company have entered Phase III clinical research (already transferred), and 4 have entered Phase I-II clinical trials. There are 6 projects under research, of which 3 are expected to file IND in 2023, and the other 3 are in CMC research.
The company has entered a period of rapid development and is planning and implementing the construction of an industrial park for recombinant biopharmaceuticals, preparations for an IPO, expansion and formation of talent teams in various aspects, and is making every effort to advance the clinical research and industrialization of multiple projects, accelerating the clinical trials and internationalization of projects under research as well as the market promotion and layout of industrial enzymes.
You can visit "" or follow the official account "Chongqing Paijin Biotechnology Co., Ltd." to learn more information.